CervoMed shares new Phase 2b RewinD-LB data

CervoMed Inc. furnished an update on its lead program by sharing new data from the RewinD-LB Phase 2b clinical trial of neflamapimod in patients with dementia with Lewy bodies.

Rhea-AI Filing Summary

CervoMed Inc. furnished an update on its lead program by sharing new data from the RewinD-LB Phase 2b clinical trial of neflamapimod in patients with dementia with Lewy bodies. The company issued a press release and also posted a detailed investor presentation on its website under “Investors – Events and Presentations,” which covers business, clinical studies, development plans and financial position along with the new trial results. This information is provided as a Regulation FD disclosure and is treated as “furnished,” not “filed,” and is also incorporated by reference into an other-events section of this report.

Insights

Biotech & SEC disclosure analyst

CervoMed highlights new Phase 2b neflamapimod data via Reg FD materials.

CervoMed is drawing attention to new results from its RewinD-LB Phase 2b trial of neflamapimod in dementia with Lewy bodies by issuing a press release and an investor presentation. The presentation also summarizes broader business, clinical programs, development plans and financial position, which can help investors better understand how this trial fits into the overall pipeline.

The company explicitly treats this as a Regulation FD communication, stating the information is being furnished rather than filed and limiting potential liability under certain securities laws. Only the first paragraph of the press release and the section titled “New Results from the Phase 2b RewinD-LB Trial” are incorporated into the other-events section, so the focal point is the new clinical data, although the excerpt does not describe the results themselves.

Because the detailed data are contained in the attached press release and posted presentation, investors looking at this update may review those materials to see how the trial outcomes relate to neflamapimod’s future development plans and the company’s broader strategy.

8-K Event Classification

3 items: 7.01, 8.01, 9.01

3 items

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

What did CervoMed Inc. (CRVO) announce in this 8-K?

CervoMed Inc. disclosed that it released a press release and an investor presentation with new data from the RewinD-LB Phase 2b clinical trial of neflamapimod in patients with dementia with Lewy bodies.

Which clinical trial is highlighted by CervoMed Inc. (CRVO)?

The update focuses on the RewinD-LB Phase 2b clinical trial of neflamapimod in patients with dementia with Lewy bodies, referred to as the RewinD-LB Trial.

Where can investors find CervoMed’s new RewinD-LB trial results and presentation?

CervoMed states that information on its business, clinical studies, development plans, financial position and the new RewinD-LB Trial results is available on its website, www.cervomed.com, under “Investors – Events and Presentations.”

How is the new CervoMed (CRVO) information treated under securities laws?

The company specifies that the information in this disclosure is being furnished under Regulation FD, not filed, and it is not subject to Section 18 liability or automatically incorporated into other Securities Act or Exchange Act filings unless specifically referenced.

Which parts of CervoMed’s press release are incorporated into the other-events section?

The information in the first paragraph of the press release and the section titled “New Results from the Phase 2b RewinD-LB Trial” are incorporated by reference into the other-events section of this report.

Will CervoMed (CRVO) update the RewinD-LB trial information going forward?

CervoMed notes it has no duty or obligation to publicly update or revise the information in the presentation except as required by law, although management may do so through future SEC reports, press releases or other public disclosures.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 10/08/2025 - 04:33 PM Learn about SEC filing dates

false 0001053691 0001053691 2025-10-08 2025-10-08

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

October 8, 2025

Date of Report (Date of earliest event reported)

CervoMed Inc.

(Exact name of registrant as specified in its charter)

Delaware	001-37942	30-0645032
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)
20 Park Plaza, Suite 424 Boston, Massachusetts		02116
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (617) 744-4400

Not applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.001 par value		CRVO		NASDAQ Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01         Regulation FD Disclosure

Press Release

On October 8, 2025, CervoMed Inc. (the “Company,” “we” or “us”) issued a press release announcing new data from the RewinD-LB Phase 2b clinical trial of neflamapimod in patients with dementia with Lewy bodies (“RewinD-LB Trial”). A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein.

Presentation

Certain information concerning the business, clinical studies, development plans, financial position and related matters of the Company, including the new results from the RewinD-LB Trial, has been made available on our website, www.cervomed.com, under the heading, “Investors – Events and Presentations.” Representatives of the Company may use this presentation, in whole or in part, and possibly with non-material modifications, periodically in connection with conferences, meetings, and presentations to investors, analysts and others.

The information contained in the presentation is summary information that is intended to be considered in the context of the Company’s filings with the U.S. Securities and Exchange Commission (“SEC”) and other public announcements that the Company may make, by press release or otherwise, from time to time. The Company undertakes no duty or obligation to publicly update or revise the information contained in the presentation except as required by applicable law, although the Company may do so from time to time as its management believes is warranted. Any such updating may be made through the filing of other reports or documents with the SEC, through press releases, or through other public disclosure. The Company makes no admission or representation as to the materiality of any information in the presentation or otherwise contained in Item 7.01 of this Current Report on Form 8-K.

--

The information in this Item 7.01 is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference into any registration statement or other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 8.01         Other Events

The information set forth in the first paragraph and the information under the heading, “New Results from the Phase 2b RewinD-LB Trial,” of the Company’s press release referred to in Item 7.01 above is incorporated by reference into this Item 8.01 of this Current Report on Form 8-K.

Item 9.01                  Financial Statements and Exhibits

(d)         Exhibits

Exhibit No.	Description
99.1	Press Release, issued October 8, 2025
104	Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: October 8, 2025	CervoMed Inc.
	By:	/s/ William Elder
	Name:	William Elder
	Title:	Chief Financial Officer & General Counsel